2. Epigenetics Anti-infection
  3. METTL3 HIV
  4. CHMA1004 dihydrochloride

CHMA1004 dihydrochloride  (Synonyms: Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1)

Art. -Nr.: HY-W037893 Reinheit: 99.38%
COA
SDS
Handling Instructions Technical Support

CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CHMA1004 dihydrochloride

CHMA1004 dihydrochloride Chemische Struktur

CAS. Nr. : 122323-88-0

Größe Preis Verfügbarkeit Menge
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 Auf Lager
Solution
10 mM * 1 mL in DMSO Auf Lager
Solid
100 mg Auf Lager
250 mg Auf Lager
500 mg Auf Lager
1 g Auf Lager
5 g Auf Lager
10 g Auf Lager
50 g   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Other Forms of CHMA1004 dihydrochloride:

CHMA1004 dihydrochloride Related Antibodies

Top Publications Citing Use of Products

2 Publications Citing Use of MCE CHMA1004 dihydrochloride

Alle HIV Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
HIV HIV-1 HIV-2

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection[1][2].

In Vitro

CHMA1004 dihydrochloride protects human stem cell-derived dopamine neurons against 6-OHDA-induced cell death[1].
CHMA1004 (Compound 4) dihydrochloride (0.001-10 μM; 48 h) induces a concentration-dependent increase in HIV-1 p24 release from ACH-2 cells[2].
CHMA1004 (10 μM; 48 h) dihydrochloride promotes the production of infectious HIV-1 viral particles in ACH-2 cells, which is verified by enhanced luciferase activity in infected TZM-bl cells[2].
CHMA1004 (10 μM; 48 h) dihydrochloride increases the m6A methylation level in mRNA of ACH-2 cells to more than twice the original level, and elevates the m6A methylation level in HIV-1 viral RNA by approximately 18%[2].
CHMA1004 (1 nM-10 μM) dihydrochloride slightly increases the m6A methylation level in mRNA of HEK-293 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CHMA1004 dihydrochloride Related Antibodies

ELISA Assay[2]

Cell Line: ACH-2 cells (harboring HIV-1 provirus)
Concentration: 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM
Incubation Time: 48 h
Result: Caused a concentration-dependent increase in HIV-1 p24 release (measured as optical density at 450 nm).
Showed statistically significant increases at 0.1 μM, 1 μM, and 10 μM compared to control.
In Vivo

CHMA1004 (1-5 mg/kg; i.p.; daily, 17-18 days; or single dose) dihydrochloride elicits anxiolytic-like and locomotor activating effects in male and female Wistar rats, alters brain monoamine levels and striatal gene expression linked to neuropsychiatric pathways, and lacks strong psychostimulant properties[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (male and female; 3 months old at study start; male body weight 499 g, female body weight 290 g)[1]
Dosage: 1 mg/kg (subchronic; acute microdialysis); 5 mg/kg (subchronic; acute microdialysis)
Administration: i.p.; daily; 17-18 days (subchronic); i.p.; single dose (acute microdialysis)
Result: Increased time spent moving, line crossings, and rearings in female rats in acute open field test.
Showed a similar non-significant tendency in males at 5 mg/kg in acute open field test.
Reduced faecal boli counts in male rats at 5 mg/kg in acute open field test.
Increased head-dips in female rats during the first repeated elevated zero-maze test at 1 mg/kg and 5 mg/kg.
Increased open quadrant entries in male rats during the second repeated elevated zero-maze test at 5 mg/kg.
Reduced stretched-attend postures in male rats during the first repeated elevated zero-maze test at 5 mg/kg.
Increased swimming time and reduced struggling time in female rats on both test days of repeated forced swimming test at 1 mg/kg and 5 mg/kg.
Tended to increase locomotion in male rats during amphetamine challenge at subchronic 5 mg/kg.
Reduced the baseline sex difference in 50-kHz USVs by increasing vocalisations in males and reducing them in females during amphetamine challenge at subchronic 5 mg/kg.
Had no significant effect on extracellular striatal dopamine levels in acute microdialysis at 1 mg/kg and 5 mg/kg.
Increased normetanephrine (NMN) levels in males and females in striatum at subchronic 5 mg/kg.
Increased the DOPAC/DA ratio in males in striatum at subchronic 5 mg/kg.
Decreased the DOPAC/DA ratio in females in striatum at subchronic 1 mg/kg.
Increased NMN levels in males in frontal cortex at subchronic 1 mg/kg and 5 mg/kg.
Increased noradrenaline (NA) levels in males in frontal cortex at subchronic 5 mg/kg.
Increased homovanillic acid (HVA) levels in males in locus coeruleus at subchronic 1 mg/kg.
Decreased HVA levels in females in locus coeruleus at subchronic 1 mg/kg and 5 mg/kg.
Increased NA levels in males and females in ventral tegmental area at subchronic 1 mg/kg.
Altered expression of 172 genes (e.g., downregulated Acsm5, Gpr83; upregulated Fgr, Hes1) in striatum of females at subchronic 1 mg/kg.
Altered expression of 120 genes (e.g., downregulated Vwa5b2, Peli1; upregulated Nbl1, Mdga1) in striatum of females at subchronic 5 mg/kg.
Showed consistent expression changes across doses in seven overlapping genes (Galns, Hps3, Misp3, Nbl1, Samd4a, Slc28a2, Spon2) in striatum of females.
Molekulargewicht

217.09

Formel

C6H14Cl2N2O2
CAS. Nr.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1NCCNC1)OC.Cl.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
Lösungsmittel & Löslichkeit
In Vitro: 

H2O : 250 mg/mL (1151.60 mM; Need ultrasonic)

DMSO : 100 mg/mL (460.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.6064 mL 23.0319 mL 46.0638 mL
5 mM 0.9213 mL 4.6064 mL 9.2128 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molaritätsrechner

  • Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (23.03 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (23.03 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Reinheit & Dokumentation

Purity: 99.38%

SDS (393 KB)

COA (250 KB) HNMR (271 KB) RP-HPLC (247 KB)

Handling Instructions (2659 KB)
Verweise

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 4.6064 mL 23.0319 mL 46.0638 mL 115.1596 mL
5 mM 0.9213 mL 4.6064 mL 9.2128 mL 23.0319 mL
10 mM 0.4606 mL 2.3032 mL 4.6064 mL 11.5160 mL
15 mM 0.3071 mL 1.5355 mL 3.0709 mL 7.6773 mL
20 mM 0.2303 mL 1.1516 mL 2.3032 mL 5.7580 mL
25 mM 0.1843 mL 0.9213 mL 1.8426 mL 4.6064 mL
30 mM 0.1535 mL 0.7677 mL 1.5355 mL 3.8387 mL
40 mM 0.1152 mL 0.5758 mL 1.1516 mL 2.8790 mL
50 mM 0.0921 mL 0.4606 mL 0.9213 mL 2.3032 mL
60 mM 0.0768 mL 0.3839 mL 0.7677 mL 1.9193 mL
80 mM 0.0576 mL 0.2879 mL 0.5758 mL 1.4395 mL
100 mM 0.0461 mL 0.2303 mL 0.4606 mL 1.1516 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CHMA1004 dihydrochloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CHMA1004122323-88-0Methyl piperazine-2-carboxylate METTL3 activator-1CHMA 1004CHMA-1004METTL3HIVMethyltransferase-like 3Human immunodeficiency virusMettl3 activatorliver fibrosisInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
CHMA1004 dihydrochloride
Art. -Nr.:
HY-W037893
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.